Consonance Capital Management LP Amarin Corp Plcuk Transaction History

Consonance Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$13.94 - $24.12 $89.1 Million - $154 Million	-6,390,259 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$13.89 - $23.16 $30.9 Million - $51.5 Million	-2,223,564 Reduced 25.81%	6,390,259 $96.9 Million
Q2 2019 Aug 14, 2019	SELL	$16.27 - $20.51 $38.7 Million - $48.8 Million	-2,377,152 Reduced 21.63%	8,613,823 $167 Million
Q1 2019 May 15, 2019	BUY	$12.61 - $22.33 $19.4 Million - $34.4 Million	1,540,212 Added 16.3%	10,990,975 $228 Million
Q4 2018 Feb 14, 2019	BUY	$12.41 - $22.98 $55.6 Million - $103 Million	4,482,100 Added 90.21%	9,450,763 $129 Million
Q2 2018 Aug 14, 2018	SELL	$2.68 - $3.48 $34.2 Million - $44.4 Million	-12,761,270 Reduced 71.98%	4,968,663 $15.4 Million
Q1 2018 May 15, 2018	SELL	$2.99 - $4.44 $20.2 Million - $30 Million	-6,746,587 Reduced 27.56%	17,729,933 $53.4 Million
Q4 2017 Feb 14, 2018	SELL	$3.06 - $4.09 $528,645 - $706,588	-172,760 Reduced 0.7%	24,476,520 $98.2 Million
Q3 2017 Nov 14, 2017	BUY	$3.03 - $3.72 $74.7 Million - $91.7 Million	24,649,280	24,649,280 $86.3 Million

179

67.8M

233K

121K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $230M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.